Literature DB >> 16864926

Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study.

Takayuki Tsuneda1, Takeshi Yamashita, Masatake Fukunami, Koichiro Kumagai, Shin-ichi Niwano, Ken Okumura, Hiroshi Inoue.   

Abstract

BACKGROUND: The present study aimed to determine whether quality of life (QOL) in permanent atrial fibrillation (AF) patients would be improved by monotherapy with beta-blocker (BB) or calcium antagonist (CAA) as compared with digitalis. METHODS AND
RESULTS: Twenty-nine patients with permanent AF under digitalis were randomized into BB (bisoprolol, atenolol or metoprolol) or CAA (verapamil) monotherapy treatment group. Twenty-five were men and the mean age was 67+/-8 years. After the assigned monotherapy, 12 patients received the other monotherapy in a cross-over fashion. Under each treatment, efficacy of rate control was determined by Holter electrocardiogram (ECG), treadmill testing and QOL questionnaire (Short Form-36 (SF-36) and Quality of Life of Atrial Fibrillation (AFQLQ)), and compared with the baseline digitalis treatment. CAA significantly increased mean and minimum heart rate (HR) in Holter ECG as compared with digitalis, whereas BB increased only minimum HR. Exercise duration in treadmill testing was significantly prolonged by CAA treatment, although it only tended to be prolonged by BB treatment. CAA but not BB improved role function-physical score of SF-36, and frequency and severity of symptoms of AFQLQ.
CONCLUSION: These results indicate that CAA is preferable to digitalis when monotherapy is selected for short-term improvement of QOL and exercise tolerance in patients with permanent AF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864926     DOI: 10.1253/circj.70.965

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  6 in total

1.  Rate control in permanent atrial fibrillation.

Authors:  Theodora Nikolaidou; Kevin S Channer
Journal:  BMJ       Date:  2007-11-24

2.  Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer.

Authors:  Takashi Nojiri; Kazuhiro Yamamoto; Hajime Maeda; Yukiyasu Takeuchi; Yasunobu Funakoshi; Ryoji Maekura; Meinoshin Okumura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-12-16

3.  Rate control drugs differ in the prevention of progression of atrial fibrillation.

Authors:  Tim Koldenhof; Petra E P J Wijtvliet; Nikki A H A Pluymaekers; Michiel Rienstra; Richard J Folkeringa; Patrick Bronzwaer; Arif Elvan; Jan Elders; Raymond Tukkie; Justin G L M Luermans; Sander M J van Kuijk; Jan G P Tijssen; Isabelle C van Gelder; Harry J G M Crijns; Robert G Tieleman
Journal:  Europace       Date:  2022-03-02       Impact factor: 5.214

4.  Effects of pharmacologic therapy on health-related quality of life in elderly patients with atrial fibrillation: a systematic review of randomized and nonrandomized trials.

Authors:  Carl J Pepine
Journal:  Clin Med Insights Cardiol       Date:  2013-01-22

5.  A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.

Authors:  Dipak Kotecha; Melanie Calvert; Jonathan J Deeks; Michael Griffith; Paulus Kirchhof; Gregory Yh Lip; Samir Mehta; Gemma Slinn; Mary Stanbury; Richard P Steeds; Jonathan N Townend
Journal:  BMJ Open       Date:  2017-07-20       Impact factor: 2.692

6.  Paroxysmal atrial fibrillation recurrences and quality of life in symptomatic patients: A crossover study of flecainide and pilsicainide.

Authors:  Tsuyoshi Shiga; Koichiro Yoshioka; Eiichi Watanabe; Hisako Omori; Masahiro Yagi; Yasuo Okumura; Naoki Matsumoto; Kengo Kusano; Chikara Oshiro; Takanori Ikeda; Naohiko Takahashi; Takashi Komatsu; Atsushi Suzuki; Tsuyoshi Suzuki; Yasuto Sato; Takeshi Yamashita
Journal:  J Arrhythm       Date:  2017-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.